BioForce Nanosciences: Financial Performance and Critical Liquidity Challenges

Persistent Financial Losses Amid Zero Revenue Generation

BioForce Nanosciences has not generated any revenue since fiscal year 2020, with the last reported sales totaling only $17,775 in 2019 [F1]. The company’s flagship product "BioForce Eclipse" registered zero unit sales during both 2024 and 2025 [S1]. Net losses have escalated markedly, rising from approximately $490,437 in 2024 to about $1.29 million in 2025. This increase is primarily attributable to a one-time loss on liability settlement amounting to roughly $801,193 in 2025 [F1][S1][S6].

Operating cash flows have consistently been negative, with a cash outflow of $65,150 recorded in fiscal year 2025 compared to -$61,250 in the prior year [F1]. This persistent cash burn highlights ongoing operational challenges without offsetting revenue inflows.

Historical performance (annual)

Source: SEC companyfacts cache [F1].

Capital returns and efficiency (annual)

Source: SEC companyfacts cache [F1].

Source: SEC filings and Companyfacts data [F1], [S1], [S6]

Business Model Status and Product Commercialization Absence

The company's stated mission is to be a provider of natural vitamins and nutritional supplements targeted at active individuals across age groups [S1][S9]. Despite this positioning and previous announcements regarding products like "BioForce Eclipse," no sales have been recorded for these products during recent years [S1]. The lack of commercial traction casts uncertainty on the company’s ability to establish brand presence or competitive differentiation within a highly fragmented supplements market.

Critical Liquidity Constraints Raise Going Concern Doubts

As of December 31, 2025, BioForce's liquidity profile was severely strained. Current assets stood at only $786 while current liabilities exceeded $619,000—resulting in a current ratio close to zero (approximately 0.001) and a working capital deficit near -$618k [F1][S1][S6]. This mismatch signals very limited liquid resources available to meet short-term obligations.

The company also carries an accumulated deficit exceeding $162 million as of year-end 2025 [F1], reflecting sustained shareholder value erosion over time. Management acknowledges that without successful capital raises through debt or equity offerings—which it plans to pursue—and relying partially on an oral funding commitment from Chairman Merle Ferguson for short-term operational support, continuation as a going concern is uncertain [S1][S6][S8].

Expense Profile Reflects High Fixed Costs Amid No Revenue

Despite absence of revenues for multiple years running, BioForce continues incurring general and administrative expenses close to $67k annually (e.g., $66,951 in FY2025), primarily related to professional service fees and administrative overheads [S1]. Total expenses for FY2025 were approximately $490k.

The spike in net loss during FY2025 is largely due to a significant one-time liability settlement loss (~$801k), which distorts trend analysis but also highlights financial risk exposures faced by the company [S6].

Capital Allocation Overview: No Returns or Buybacks Amid Deficits

With no dividends or share repurchases disclosed and operating cash flows consistently negative (-$65k in FY2025), BioForce's capital allocation focuses exclusively on sustaining operations through external financing efforts rather than returning capital to shareholders [F1][S6]. The large accumulated deficit ($162 million+) combined with negative equity (~-$618k) precludes meaningful return on equity calculations or distributions at this stage.

Strategic Partnerships and Growth Outlook Remain Uncertain

While historical disclosures mention a memorandum of understanding signed with Element Global Inc. aimed at strategic collaboration announced in prior years , there is no clear evidence that such alliances have translated into revenue growth or material operational progress through fiscal year-end 2025.

The absence of disclosed guidance or milestones beyond general intent constrains visibility on future growth trajectories. Key inflection points include achieving initial product sales volumes; securing binding commercial contracts; successfully raising capital beyond informal funding commitments; reducing operating losses excluding nonrecurring items; and demonstrating operational scalability.

Risks Highlighted by Management Disclosures

The company’s SEC filings emphasize substantial doubt about its ability to continue as a going concern absent additional funding due to ongoing losses and liquidity shortfalls [S5][S7]. Regulatory complexities inherent in nutritional supplement markets add further layers of risk given quality control requirements and competitive pressures.

Summary Table: Key Financial Metrics (USD)

Note: Parentheses indicate negative values.

This analysis strictly reflects publicly available information as detailed in BioForce Nanosciences Holdings’ SEC filings up to April 15th, 2026. It does not constitute investment advice but offers a factual assessment based on disclosed financials and corporate narratives.

Disclaimer: This is research-only, informational analysis and not investment advice. It may include AI-generated interpretation and general industry context. Always verify important details using primary sources.